Method of Treatment for Ketamine Infusion
Methods for treatment for patients having depression and/or pain are contemplated as including an administration of first preparation comprising an antiemetic agent, preferably ondansetron, followed by a second preparation of a synergistic combination of ketamine and a benzodiazepine, preferably lorazepam, administered via a continuous intravenous infusion. Such methods may be seen to better alleviate depression and pain symptoms, and may result in reduced need for other medications.
1 . A method of treating a patient having a depression condition in need of treatment, the method comprising:
administering to the patient a first preparation, the first preparation comprising a pharmacologically effective amount of an antiemetic agent; and
administering to the patient a second preparation, the second preparation being an intravenous infusion comprising a mixture of a pharmacologically effective amount of ketamine and a pharmacologically effective amount of a benzodiazepine.
2 . The method of claim 1 , wherein the antiemetic agent of the first preparation comprises at least one compound selected from the group comprising: non-selective 5-HT antagonist, 5-HT 3 receptor antagonist, 5-HT 4 receptor agonist, CB 1 agonist, D2 receptor antagonist, D3 receptor antagonist, GABA receptor agonist, Hi receptor antagonist, muscarinic acetylcholine receptor antagonist, NK 1 receptor antagonist, or combinations thereof.
3 . The method of claim 2 , wherein the first preparation comprises an intravenous infusion of ondansetron.
4 . The method of claim 1 , wherein in the second preparation, the benzodiazepine is selected from the group comprising: 1,4-benzodiazepine, 1,5-benzodiazepine, 2,3-benzodiazepine, triazolobenzodiazepine, imidazobenzodiazepine, oxazolobenzodiazepine, thienodiazepine, thienotriazolodiazepine, thienobenzodiazepine, pyridodiazepine, pyridotriazolodiazepine, pyrralodiazepine, tetrahydroisoquinobenzodiazepine, a benzodiazepine prodrug, or combinations thereof.
5 . The method of claim 4 , wherein the benzodiazepine comprises lorazepam.
6 . The method of claim 1 , wherein in the second preparation, the ratio of ketamine to benzodiazepine is between 100:1 and 10:1 by weight.
7 . The method of claim 1 , wherein the second preparation is administered as a saline solution.
8 . The method of claim 1 , wherein the second preparation additionally comprises a pharmacologically effective amount of one or more of: an anesthetic, a sedative, an antiemetic, an anticonvulsant, an antidepressant, an antimigraine, an antipsychotic, an anxiolytic, an antiparkinson.
9 . The method of claim 8 , wherein the second preparation additionally comprises ondansetron.
10 . The method of claim 1 , further comprising administering to the patient a third preparation, the third preparation comprising a pharmaceutically effective amount of an anti-inflammatory agent.
11 . The method of claim 10 , wherein the third preparation comprises an intravenous infusion of ketorolac.
12 . The method of claim 10 , wherein the third preparation comprises an intramuscular infusion of a pharmaceutically effective amount of a triptan.
13 . The method of claim 12 , wherein the third preparation comprises sumatriptan.
14 . The method of claim 1 , wherein the second preparation is administered via continuous intravenous infusion at a rate of between 20 and 150 mg of ketamine per hour
15 . The method of claim 1 , wherein the second preparation is administered via continuous intravenous infusion at a rate of between 40 and 100 mg of ketamine per hour.
16 . The method of claim 14 , wherein the rate of administration of the second preparation is configured to vary during the period of administration.
17 . The method of claim 16 , wherein the second preparation is initially delivered at a first rate of between 40-60 mg of ketamine per hour, subsequently delivered at a second rate of between 80-120 mg of ketamine per hour, and finally delivered at a third rate of about 20-40 mg of ketamine per hour.
18 . The method of claim 1 , wherein during the administration of the second preparation, at least about 0.5 mg of ketamine is delivered to the patient per kg of the patient's body mass.
19 . The method of claim 1 , wherein the administration of the second preparation is performed over a time period of at least an hour.
20 . A method of treating a patient having a condition, evidenced by symptoms, in need of treatment, the method comprising:
administering to the patient a first preparation, the first preparation comprising a pharmacologically effective amount of an antiemetic agent; and
administering to the patient a second preparation, the second preparation comprising a mixture of a pharmacologically effective amount of ketamine and a pharmacologically effective amount of a benzodiazepine.